SAREPTA THERAPEUTICS, INC. Q3 2019 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, priorities and research and development programs including: our plan to work diligently to address the reasons for the CRL and determine a pathway for a potential approval of golodirsen; our intention to await clarity on the CRL before we submit an NDA for casimersen in the U.S.; the potential to build 5 constructs in addition to SRP-5051 and to treat as much as 43% of the DMD patient population if our PPMO shows encouraging results; SRP-9001 being the highest potential late-stage gene therapy program currently in biotech; the goal of the AAVance gene therapy study for MPS3A of robustly expressing the missing enzyme in the brain that causes MSP3A; the potential applicability of NT-3 not only in CMT 1A but beyond to other neurodegenerative diseases; Sarepta's potential to be among the most significant gene therapy and genetic medicine biotechnology companies in existence; Sarepta being in a strong position to continue to accelerate our strategic imperatives and invest in the growth of Sarepta; our revenue guidance for 2019 of $370 to $380M for EXONDYS 51; the expectation that our strategy to advance the very best science, build awareness and appreciation for Duchenne, and pave new pathways so all eligible Duchenne patients gain access to therapy will play a role for future therapies; the expectation that if golodirsen is approved, we will be ready to launch, leveraging our knowledge and experience to facilitate rapid access to individuals amenable to exon 53; our gene therapy site readiness goal and plan to focus on this as we move through worldwide development and, if successful, commercialization; the potential of our commercial team to support multiple launches in the years to come; Sarepta's prospects to transform the lives of patients with rare diseases bring unparalleled in the industry; and our current plans and expected milestones, including to begin dosing patients in our confirmatory trial for Exondys 51 in the fourth quarter of 2019, to obtain safety and dosing insight for our PPMO program in the first half of 2020, to lock process development for SRP-9001 manufacturing and commence a multi-center, multi-country, placebo-controlled study using commercial process material by mid-2020, to initiate a separate study for older and non-ambulatory patients as well, to complete dosing in study 2 of SRPT 9001 by year end, with functional read out at 48 weeks thereafter, to dose an additional high dose cohort for LGMD 2E and then early in 2020 make dose selection, to meet with the FDA in the near term to discuss the development pathway for our LGMD programs and present an update on the development path and timeline for our entire LGMD portfolio, to commence dosing of the proof of concept study for CMT 1A, subject to obtaining final release of trial material from NCH for the study, to continue to place resources on patient identification programs, to continue to work with payers to support broad access to our gene therapy product candidates, to leverage our knowledge and experience to ensure that we are able to serve the LGMD communities as we have in Duchenne.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to EXONDYS 51 sales or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with FDA post-approval commitments and requirements with respect to EXONDYS 51 in a timely manner or at all; Sarepta's dependence on certain manufacturers to produce its product candidates, including any inability on Sarepta's part to accurately anticipate product demand and timely secure manufacturing capacity, may impair the availability of product to successfully support various programs; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; our data for golodirsen, casimersen, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; current reimbursement models may not accommodate the unique factors of our gene therapy product candidates; Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of Sarepta's control, including possible limitations of company financial and other resources, manufacturing limitations, reimbursement hurdles and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta's product candidates; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2018 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.